Clinical Trials Browser

OTHER × Neoplasms × tremelimumab × Clear all

NCT03911557 2025-11-12

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Phase 2 Completed

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms